Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Other Operating Expenses (2017 - 2024)

Avalo Therapeutics filings provide 7 years of Other Operating Expenses readings, the most recent being $87000.0 for Q4 2024.

  • On a quarterly basis, Other Operating Expenses fell 97.64% to $87000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was $87000.0, a 99.72% decrease, with the full-year FY2024 number at $27.3 million, up 425.43% from a year prior.
  • Other Operating Expenses hit $87000.0 in Q4 2024 for Avalo Therapeutics, up from -$714000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $27.5 million in Q1 2024 to a low of -$714000.0 in Q3 2024.
  • Median Other Operating Expenses over the past 4 years was $655500.0 (2021), compared with a mean of $2.5 million.
  • The widest YoY moves for Other Operating Expenses: up 4883.3% in 2024, down 389.07% in 2024.
  • Avalo Therapeutics' Other Operating Expenses stood at $691000.0 in 2021, then dropped by 10.27% to $620000.0 in 2022, then soared by 494.52% to $3.7 million in 2023, then tumbled by 97.64% to $87000.0 in 2024.
  • The last three reported values for Other Operating Expenses were $87000.0 (Q4 2024), -$714000.0 (Q3 2024), and $446000.0 (Q2 2024) per Business Quant data.